人胰腺癌细胞CFPAC1
BLUEFBIO™ Product Sheet
|
细胞名称 |
人胰腺癌细胞CFPAC1 |
|
|
|
货物编码 |
BFN60808541 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 2类 |
||
|
培养体系 |
DMEM高糖+10%FBS+1%三抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人胰腺癌细胞CFPAC1取自26岁男性供体。该细胞源于ATCC |
||
|
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: NCI RAS program mutant KRAS cell line panel. Doubling time: 30 hours (at 17th passage), 32 hours (at 74th passage) (PubMed=1692630); 45 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: Deep quantitative proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Metabolome analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: Proteome analysis by 2D-DE/MS. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Misspelling: CFPANC1; In CGH-DB 164-1. |
||
|
基因突变 |
Homozygous for CFTR p.Phe508del (c.1521_1523delCTT) (PubMed=15463957; ATCC). Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP). Homozygous for SMAD4 deletion (PubMed=10408907; PubMed=11169959; PubMed=11787853; PubMed=15367885). Homozygous for TP53 p.Cys242Arg (c.724T>C) (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP). |
||
|
HLA信息 |
/ |
||
|
STR信息 |
Amelogenin X,Y CSF1PO 10 D2S441 10,14 D2S1338 18,23 D3S1358 16 D5S818 10,11 D6S1043 20 D7S820 8,10 D8S1179 11,15 D12S391 17 D13S317 12 D16S539 9,11 D18S51 12 D19S433 13,15 D21S11 30,31.2 FGA 21,22 Penta D 11,13 Penta E 10,12 TH01 8 TPOX 8 vWA 17
|
||
|
参考文献 |
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402(2020) |
||
